Your browser doesn't support javascript.
loading
Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study.
Moschos, Stergios J; Sandhu, Shahneen; Lewis, Karl D; Sullivan, Ryan J; Puzanov, Igor; Johnson, Douglas B; Henary, Haby A; Wong, Hansen; Upreti, Vijay V; Long, Georgina V; Flaherty, Keith T.
Afiliación
  • Moschos SJ; Department of Medicine, Division of Medical Oncology, The University of North Carolina at Chapel Hill and the Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA. moschos@med.unc.edu.
  • Sandhu S; Department of Medical Oncology, Peter MaCallum Cancer Center and the University of Melbourne, Melbourne, VIC, Australia.
  • Lewis KD; Division of Medical Oncology, Anschultz Medical Campus, University of Colorado, Denver, CO, USA.
  • Sullivan RJ; Developmental Therapeutics and Melanoma Programs, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
  • Puzanov I; Department of Medicine, Vanderbilt University Medical Center and Ingram Cancer Center, Nashville TN, USA.
  • Johnson DB; Department of Medicine, Vanderbilt University Medical Center and Ingram Cancer Center, Nashville TN, USA.
  • Henary HA; Medical Affairs, Amgen Inc, Thousand Oaks, CA, USA.
  • Wong H; Clinical Pharmacology, Modeling & Simulation, Amgen Inc, South San Francisco, CA, USA.
  • Upreti VV; Clinical Pharmacology, Modeling & Simulation, Amgen Inc, South San Francisco, CA, USA.
  • Long GV; Melanoma Institute Australia, The University of Sydney and Royal North Shore, and Mater Hospitals, Sydney NSW, Australia.
  • Flaherty KT; Developmental Therapeutics and Melanoma Programs, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Invest New Drugs ; 40(5): 1051-1065, 2022 10.
Article en En | MEDLINE | ID: mdl-35635631
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteína p53 Supresora de Tumor / Melanoma Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Invest New Drugs Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteína p53 Supresora de Tumor / Melanoma Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Invest New Drugs Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos